163.86 USD
-2.73 (-1.64%)
163.86 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to RGEN. RGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
RGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RGEN has a Return On Assets of 0.06%. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
Looking at the Return On Equity, with a value of 0.08%, RGEN is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a better Profit Margin (0.25%) than 68.42% of its industry peers.
The Operating Margin of RGEN (6.58%) is better than 63.16% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin (51.59%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RGEN has more shares outstanding
Compared to 5 years ago, RGEN has more shares outstanding
Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.60 indicates that RGEN is not in any danger for bankruptcy at the moment.
The Altman-Z score of RGEN (7.60) is better than 85.96% of its industry peers.
The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
RGEN has a Debt to FCF ratio of 5.05. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 50.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.6 |
ROIC/WACC0.1
WACC10.46%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a Current ratio of 8.36. This is amongst the best in the industry. RGEN outperforms 91.23% of its industry peers.
RGEN has a Quick Ratio of 7.14. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.14, RGEN belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
The Revenue has decreased by -8.54% in the past year.
RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.53% yearly.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
RGEN is valuated quite expensively with a Price/Earnings ratio of 98.71.
RGEN's Price/Earnings is on the same level as the industry average.
RGEN is valuated expensively when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 77.79.
RGEN's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.13. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.71 | ||
| Fwd PE | 77.79 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 86.62 | ||
| EV/EBITDA | 82.6 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.48% in the coming years.
PEG (NY)6.65
PEG (5Y)13.89
EPS Next 2Y19.3%
EPS Next 3Y22.48%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
163.86
-2.73 (-1.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners110.01%
Inst Owner Change16.45%
Ins Owners0.45%
Ins Owner Change-2.87%
Market Cap9.22B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target193.06 (17.82%)
Short Float %7.85%
Short Ratio4.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.98%
PT rev (3m)5.47%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)-12.15%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-0.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.71 | ||
| Fwd PE | 77.79 | ||
| P/S | 13.03 | ||
| P/FCF | 86.62 | ||
| P/OCF | 70.47 | ||
| P/B | 4.43 | ||
| P/tB | 16.04 | ||
| EV/EBITDA | 82.6 |
EPS(TTM)1.66
EY1.01%
EPS(NY)2.11
Fwd EY1.29%
FCF(TTM)1.89
FCFY1.15%
OCF(TTM)2.33
OCFY1.42%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)6.65
PEG (5Y)13.89
Graham Number37.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.6 |
F-Score6
WACC10.46%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.03%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.